Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Research provides insight into new drug resistance in hospital microbes

14.07.2011
Mass. Eye and Ear, Harvard Medical School investigators share finding in July 2011 issue of Antimicrobial Agents and Chemotherapy

Hospitals struggle to prevent the infections that complicate treatment for cancer, joint replacement, heart surgery and other conditions. Hospital-acquired infections are often resistant to multiple antibiotics, leading to approximately 100,000 deaths and more than $30 billion in additional health care costs yearly. New drugs are being developed to combat these infections, but resistance invariably emerges to these last-line drugs.

Daptomycin, a new antibiotic approved by the FDA in 2003, is used to treat infections caused by multi-drug resistant bacteria, including staph and microbes known as enterococci. Scientists in the Department of Ophthalmology at Mass. Eye and Ear and Harvard Medical School, and the pharmaceutical company Cubist, which produces daptomycin under the trade name Cubicin, teamed up to discover the basis for resistance that has now begun to emerge to daptomycin in the enterococci. Their discovery of a new mechanism of resistance is described in an article in the current (July) issue of Antimicrobial Agents and Chemotherapy.

In a two-week experiment, investigators were able recreate the development of resistance in the laboratory in a manner similar to that which occurred in the hospital. Using new genome sequencing technology, they resequenced the entire genome of the resistant enterococcus strain to identify all of the genetic changes. The researchers found changes in genes that they were also able to identify in hospital daptomycin resistant strains. Mutations in a gene encoding an enzyme called cardiolipin synthase were able by itself to confer daptomycin resistance to a laboratory strain of enterococcus.

"Knowing the changes that correspond with resistance not only tells us what happens in resistant strains, it tells us much about how exactly how the antibiotic works, providing new ideas for better treatment and next generation drugs," observed Dr. Michael S. Gilmore, a scientist at Harvard Medical School and the Mass. Eye and Ear, and the corresponding author.

Dr. Gilmore credits a large part of the success of this study to the genomics skills of first author and postdoctoral associate Dr. Kelli Palmer, and to the collaboration with industry partners Dr. Jared Silverman and colleagues from Cubist Pharmaceuticals, Inc. Drs. Gilmore and Silverman have been collaborating in a university/industry partnership, the Harvard-wide Program on Antibiotic Resistance, which aims to build interdisciplinary teams to understand resistance and develop new treatments for resistant infections.

Authors: Kelli L. Palmer, Anu Daniel, Crystal Hardy, Jared Silverman, and Michael S. Gilmore (list of affiliations available in the PDF)

Grant Support: Portions of this work were supported by NIH grant AI072360 (to M.S.G), the Harvard-wide Antibiotic Resistance Project AI083214, NIH fellowship support grant to EY020734 to K.L.P., and Cubist Pharmaceuticals, Inc.

About Mass. Eye and Ear

The Mass. Eye and Ear/Mass General Department of Ophthalmology is one of the world's premier centers for excellence in ophthalmic clinical care, research and education. Steadfast dedication to an integrated three-part mission keeps the Department at the forefront of advances in patient care and scientific discovery, while training and advancing generations of leaders through our academic and professional development programs. As the seat of Ophthalmology leadership for Harvard Medical School, the Department builds on the strengths of affiliated faculty from such renowned local institutions as Joslin Diabetes Center, Children's Hospital Boston, Schepens Eye Research Institute, Brigham and Women's Hospital, Beth Israel Deaconess Medical Center and Boston Veteran's Administration Healthcare System to encourage innovation and remain a global leader in ophthalmology.

Founded in 1824, Mass. Eye and Ear is an independent specialty hospital, an international center for treatment and research, and a teaching affiliate of the Harvard Medical School.

For more information, call (617) 523-7900 or TDD (617) 523-5498 or visit www.MassEyeAndEar.org.

Mary Leach | EurekAlert!
Further information:
http://www.MassEyeAndEar.org

More articles from Life Sciences:

nachricht Building a brain, cell by cell: Researchers make a mini neuron network (of two)
23.05.2018 | Institute of Industrial Science, The University of Tokyo

nachricht Research reveals how order first appears in liquid crystals
23.05.2018 | Brown University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

Im Focus: Entangled atoms shine in unison

A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.

The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

Building a brain, cell by cell: Researchers make a mini neuron network (of two)

23.05.2018 | Life Sciences

One-way roads for spin currents

23.05.2018 | Physics and Astronomy

A simple mechanism could have been decisive for the development of life

23.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>